Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ENSC
stocks logo

ENSC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
502.97K
-61.42%
-1.260
-56.55%
0.00
-100%
-0.820
-41.01%
0.00
-100%
-0.460
-41.77%
Estimates Revision
The market is revising No Change the revenue expectations for Ensysce Biosciences, Inc. (ENSC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.65%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-23.65%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Ensysce Biosciences Inc (ENSC.O) is -0.56, compared to its 5-year average forward P/E of -2.25. For a more detailed relative valuation and DCF analysis to assess Ensysce Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.25
Current PE
-0.56
Overvalued PE
1.41
Undervalued PE
-5.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.28
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.27
Undervalued EV/EBITDA
-0.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
652.87
Current PS
0.00
Overvalued PS
2709.84
Undervalued PS
-1404.10
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ENSC News & Events

Events Timeline

(ET)
2025-12-02
17:00:00
Ensysce Biosciences Files to Sell 4.6M Shares of Common Stock for Holders
select
2025-12-02
08:41:00
Ensysce Secures New Patent for MPAR Technology Until 2042
select
2025-11-17 (ET)
2025-11-17
08:27:57
Ensysce Biosciences obtains $4 million in funding
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-24Newsfilter
Ensysce Secures FDA Approval for PF614 Commercial Production Pathway
  • Positive FDA Feedback: Ensysce Biosciences received written responses from the FDA confirming the appropriateness of its regulatory starting materials and specifications for PF614. This feedback provides Ensysce with a direct path to commercial production, marking a significant milestone in its drug development journey.
  • Strengthened Partnerships: Ensysce is initiating commercial production of PF614 in collaboration with Purisys, LLC. This partnership will accelerate the market launch of the new analgesic, addressing the growing demand for safer pain relief options.
  • Innovative Product Outlook: PF614 is Ensysce's TAAP™ oxycodone analogue and the leading product in its next-generation analgesic pipeline. Designed to provide safer pain relief while minimizing the risk of abuse and overdose, it holds significant market potential.
  • Increased Executive Confidence: Ensysce CEO Dr. Lynn Kirkpatrick stated that the FDA's feedback enables the company to expedite PF614's market pathway, further solidifying its leadership in the analgesic market. This progress will help improve patient quality of life and meet the urgent market demand for safe pain medications.
[object Object]
Preview
4.0
11-18Benzinga
Ensysce Biosciences Under Review: Zacks Small-Cap Research Assigns $16.45 Price Target

  • Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.

  • Market Winning Tools: Benzinga Pro is designed to help traders gain an edge in the markets with accurate stock market intelligence.

[object Object]
Preview
6.5
08-15Newsfilter
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

  • Ensysce Biosciences Updates: Ensysce Biosciences has made significant progress in its opioid therapeutic pipeline, including the launch of the PF614 Phase 3 trial and advancements in its overdose protection programs, supported by a $5.3 million NIDA grant.

  • Financial Performance: The company reported a narrower net loss of $1.7 million for Q2 2025, attributed to increased federal grant revenue, while maintaining a valuation of $22.00 per share based on successful execution of its clinical plans.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ensysce Biosciences Inc (ENSC) stock price today?

The current price of ENSC is 1.63 USD — it has increased 2.52 % in the last trading day.

arrow icon

What is Ensysce Biosciences Inc (ENSC)'s business?

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

arrow icon

What is the price predicton of ENSC Stock?

Wall Street analysts forecast ENSC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENSC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ensysce Biosciences Inc (ENSC)'s revenue for the last quarter?

Ensysce Biosciences Inc revenue for the last quarter amounts to 493.10K USD, decreased -85.58 % YoY.

arrow icon

What is Ensysce Biosciences Inc (ENSC)'s earnings per share (EPS) for the last quarter?

Ensysce Biosciences Inc. EPS for the last quarter amounts to -1.29 USD, decreased -229.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ensysce Biosciences Inc (ENSC)'s fundamentals?

The market is revising No Change the revenue expectations for Ensysce Biosciences, Inc. (ENSC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.65%.
arrow icon

How many employees does Ensysce Biosciences Inc (ENSC). have?

Ensysce Biosciences Inc (ENSC) has 7 emplpoyees as of December 05 2025.

arrow icon

What is Ensysce Biosciences Inc (ENSC) market cap?

Today ENSC has the market capitalization of 5.88M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free